Xtant Medical Holdings, Inc. provides regenerative medicine products and medical devices for orthopedic and neurological surgeons in the United States and internationally. It offers OsteoSponge, a natural scaffold for cellular in-growth; OsteoSelect DBM Putty, a moldable demineralized bone matrix; OsteoSelect PLUS DBM Putty to deliver handling properties and ensure patient safety through validated and terminal sterilization; 3Demin, a family of allografts that maximizes osteoconductivity and the osteoinductive potential of human bone; OsteoFactor Pro, a processed allograft that contains retained growth factors found within the endosteum layer of allograft bone; OsteoVive Plus, an aseptically processed and viable bone allograft; and nanOss products that provide osteoconductive nano-structured hydroxyapatite and an engineered extracellular matrix bioscaffold collagen carrier. It also provides sports allografts for anterior and posterior cruciate ligament repairs, anterior cruciate ligament reconstruction, and meniscal repair; milled spinal allografts for cortical bone milled to desired shapes and dimensions; and traditional allografts for orthopedics, neurology, podiatry, oral/maxillofacial, genitourinary, and plastic/reconstructive applications. In addition, it offers cervical products comprising Spider cervical plating, Streamline OCT system, and CervAlign systems; thoracolumbar products, such as of Axle-X interspinous fusion, Streamline MIS spinal fixation, Streamline TL spinal fixation, and HPS 2.0 hybrid performance systems; Silex sacroiliac joint fusion systems; interbody products comprising Calix for cervical and thoracolumbar applications, Irix-C Cervical and Irix-A lumbar integrated dusion systems, and Fortilink implants; Contact ALP (Anterior Lumbar Plate) System; and interlaminar stabilization products, such as Coflex device for lumbar spinal stenosis; and CoFix implants for back and disc pain. The company is headquartered in Belgrade, Montana.…
Xtant Medical Reports Third Quarter 2026 Financial Results and Announces Board-led Strategic Review Process
Xtant Medical Holdings (NYSEAMERICAN: XTNT) is listed on NYSE American, where its shares trade in USD. It belongs to the Medical Devices industry, part of the Healthcare sector, and reports about 151 employees.
The shares were at 0.2100 USD on 20 November 2026, down 72.0% over 52 weeks. Its 52-week range is 0.1700 USD to 0.8400 USD: the price is 75.0% below the high and 23.5% above the low.
Its market capitalisation is 29.49M USD.
Xtant Medical Holdings reports return on equity of 9.8%, an operating margin of -11.0% and revenue down 27.0% year over year.
Its debt exceeds its cash by 17.10M USD, a debt-to-equity ratio of 0.56. Its Piotroski F-score is 9 out of 9, a strong reading of its financial health. 2 analysts cover the stock, with an average rating of Buy; their mean price target of 0.7500 USD is 257.1% above the current price. The next earnings report is expected on 3 March 2027.